Comparison of DPP-4 inhibitors, vildagliptin and linagliptin in type2 diabetes

Not Applicable

• Conditions: Type 2 diabetes mellitus

• Registration Number: JPRN-UMIN000010445
• Lead Sponsor: Yokohama City University Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-04-09
• Study Completion: 2017-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Not provided

Exclusion Criteria

1)severe ketosis, diabetic coma within 6 months 2)severe infection, before operation, severe trauma 3)severe hepatic dysfunction 4)or severe renal dysfunction (SCr:more than 2.0mg/dl or eGFR less than 30) 5)pregnacy 6)Allergy for vildagliptin, linagliptin, repaglinide and glimepiride 7)Patients judged by the investigator to be ineligible for some other reason

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduction rate of HbA1c after treatment with vlidagliptin or linagliptin

Secondary Outcome Measures

Name	Time	Method
1)Achievment rate of <7.0% at 4 months 2)Achievement rate of <7.0% at 8months 3)Renal function 4)glycemic control 5)lipid control 6)Achievement rate of <6.5%